3On E,Nussmeier NA,Duke PC,et al.Efficacy and safety of the cyclooxygenase 2 inhibitors parecpxib and valdecoxib in patients undergoing coronary artery bypass surgery.J Thorac Cardiovasc Surg,2003,125(6):1481-1492.
4Hubbard RC,Naumann TM,Traylor L,et al.Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia.Br J Anaesth,2003,90(2):166-172.
5Malan TP Jr,Marsh G,Hakki SI,et al.Parecoxib sodium,a parenteral cyclooxygenase 2 selective inhibitor,improves morphine analgesia and is opioid-sparing following total hip arthroplasty.Anesthesiology,2003,98(4):950-956.
1[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5～18.
2[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145～157.
3[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23～28.
4[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364～369.
5[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083～ 1091.
6[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ～222.
7[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
8[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899～1905.
9[9]Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet, 1994 ;34 3 :107 5-107 8
10[10]Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. am J Med, 1999;106:13～23.
6Pandazi A,Kapota E,Matsota P.Preincisional versus postinci-sional administration of parecoxib in colorectal surgery:effect on postoperative pain control and cytokine response:a randomized clinical trial.World J Surg,2010,34(10):2463-2469.
7Talley J J, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenyli- soxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem, 2000, 43 ( 5 ) :775-777.
8Tallcy J J, Bertenshaw SR, Brown DL, et al. N-[[(5-methyl-3- phenylisoxazol-4-yl ) phenyl] sulfoyl] propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem, 2000, 43 (9) : 1661-1663.
9Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i. m. ) parecoxib sodium in normal subjects. J Clin Pharmacol,2001,41(10) : 1111-1119.
10Keshetty S,Venisetty RK,Molmoori V, et al. Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. Pharmazie, 2006, 61(3) :245-246.
